Nutromics Receives FDA Breakthrough Device Designation

Melbourne, Australia, September 10, 2026

Nutromics Advances Wearable Epilepsy Monitoring

The NeuroPatch™ system is being developed to provide continuous, real-time monitoring of therapeutic drug levels without requiring patients to undergo repeated conventional blood draws. The wearable platform uses a microneedle-based sensor designed to access interstitial fluid and measure concentrations of anti-seizure medications. Therapeutic drug monitoring is particularly important for medications with a narrow therapeutic window, where concentrations that are too low may fail to control seizures while excessive exposure can increase the risk of adverse effects. Conventional monitoring generally relies on intermittent blood sampling, which provides only a snapshot of medication concentration and may not capture changes occurring between clinical visits. Nutromics aims to address this limitation through a continuous monitoring approach. The NeuroPatch platform is designed to collect medication-level information over time, potentially providing clinicians with a more detailed picture of how a patient’s drug concentration changes during treatment. The company believes that access to continuous pharmacokinetic information could support more informed dosing decisions and help clinicians better understand individual differences in drug absorption, metabolism and clearance. However, the NeuroPatch remains an investigational technology, and its clinical performance and ability to improve patient outcomes will require further validation.

Breakthrough Device Designation Supports Development

The FDA’s Breakthrough Device Program is intended for certain medical devices that provide more effective treatment or diagnosis for patients with life-threatening or irreversibly debilitating diseases or conditions. The designation can facilitate interactions between the FDA and device developers during the regulatory process and may support more efficient development and review. For Nutromics, the designation represents an important regulatory milestone for NeuroPatch as the company works toward advancing the platform through clinical development and regulatory evaluation. The technology is being positioned as a potential alternative to conventional intermittent therapeutic drug monitoring for patients receiving anti-seizure medications. Epilepsy affects millions of people worldwide, and achieving consistent seizure control can require careful adjustment of medication regimens. Treatment response can vary substantially between individuals because of differences in drug metabolism, adherence, interactions with other medicines and physiological factors. A continuous monitoring system could potentially help identify changes in drug exposure that might otherwise remain undetected between blood tests. This could provide clinicians with additional information when evaluating whether a patient’s current medication regimen is maintaining an appropriate therapeutic concentration. The Breakthrough Device designation does not constitute FDA approval or clearance, and it does not establish that NeuroPatch has demonstrated clinical benefit. Further clinical and regulatory work will be required before the system could potentially become commercially available in the United States.

NeuroPatch Combines Sensors and Wearable Technology

Nutromics’ technology combines wearable medical devices, biosensors and digital health capabilities to enable continuous measurement of biomarkers and therapeutic drug concentrations. The company’s platform uses minimally invasive microneedles to access interstitial fluid beneath the skin, where analytes can be measured without traditional venous blood collection. The NeuroPatch development program initially focuses on anti-seizure medications, with the potential to expand the underlying technology to additional therapeutic areas requiring continuous therapeutic drug monitoring. The platform could potentially provide value beyond simply measuring medication concentrations. Continuous data could support personalized dosing, help identify pharmacokinetic variability and provide healthcare professionals with more frequent information for treatment optimization. Nutromics is also developing its broader wearable molecular monitoring platform for applications in areas where real-time biological measurements could improve clinical decision-making. The company believes that continuous monitoring may ultimately support a shift from episodic laboratory testing toward more responsive and personalized care. The FDA Breakthrough Device Designation marks an important step in Nutromics’ efforts to bring continuous therapeutic drug monitoring into clinical practice. If subsequent studies demonstrate that NeuroPatch can accurately and reliably measure anti-seizure medication levels and provide clinically meaningful information, the technology could offer a new approach to managing patients with epilepsy. Further clinical studies and regulatory review will determine whether the wearable platform can translate its technological capabilities into improved medication management and patient care.

Source: Nutromics press release